Angiotensinogen (AGT) is the unique substrate of all angiotensin peptides. We review the recent preclinical research of AGT antisense oligonucleotides (ASOs), a rapidly evolving therapeutic approach. The scope of the research findings not only opens doors for potentially new therapeutics of hypertension and many other diseases, but also provides insights into understanding critical physiological and pathophysiological roles mediated by AGT.

Document Type


Publication Date


Notes/Citation Information

Published in Bioscience Reports, v. 39, issue 1, BSR20180201, p. 1-10.

© 2019 The Author(s).

This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).

Digital Object Identifier (DOI)


Funding Information

The authors’ research work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health [grant numbers R01HL139748, R01HL133723] and the National Natural Science Foundation of China [grant numbers 81320108003, 31371498 (to Y.W.)]; Employees of Ionis Pharmaceuticals, Inc. [to A.E.M. and R.M.C.]; M.J.G. was an employee of Ionis Pharmaceuticals, Inc.